Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Thoracic 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 47Lung Neoplasms 43Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 26Multiple Myeloma 24Glioma 22Pancreatic Neoplasms 21Carcinoma, Renal Cell 21Lymphoma, Large B-Cell, Diffuse 20Ovarian Neoplasms 19Melanoma 19Glioblastoma 19Squamous Cell Carcinoma of Head and Neck 18Lymphoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Triple Negative Breast Neoplasms 14Brain Neoplasms 14Fallopian Tube Neoplasms 13Carcinoma 13Laryngeal Neoplasms 12Carcinoma, Hepatocellular 12Astrocytoma 12Leukemia, Myeloid, Acute 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Sunitinib 2Everolimus 2sargramostim 1montanide ISA 51 1lutetium Lu 177 dotatate 1lanreotide 1incomplete Freund's adjuvant 1fludarabine phosphate 1cabozantinib 1belzutifan 1X-Rays 1Temozolomide 1Phantoms, Imaging 1Octreotide 1Methods 1Interleukin-13 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1Blood Specimen Collection 1Biopsy 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡